NCT05885425

Brief Summary

Objective: to evaluate the possibilities and effect of telemedicine monitoring and management of patients with CHF (compared to patients with CHF without intensive telemedicine monitoring) on quality of life, prognosis and the presence of complications and hospitalisations. Patients with a stable form of congestive heart failure will be gradually included in the study. Half of them will be defined by random selection to intervention group. Parameters, that can be measured at home will be periodically telemedical monitored. In according with at home monitored data, the own physician will be able to intervene with change of medical treatment in the case of non-physiological deviations in order to improve the health status as well as the prognosis of the patient with CHF.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 22, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 2, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

June 2, 2023

Status Verified

May 1, 2023

Enrollment Period

8 months

First QC Date

May 22, 2023

Last Update Submit

May 22, 2023

Conditions

Keywords

Congestive Heart Failure, Telemedicine

Outcome Measures

Primary Outcomes (2)

  • Hospitalization for cardiac reasons

    6 months

  • Visit to the emergency room (urgent)

    6 months

Secondary Outcomes (4)

  • Unplanned visit to cardiology / internist

    6 months

  • Calling Quick Medical Assistance home

    6 months

  • Fundamental change of treatment (new type of drug, change of drug group, increased dose)

    6 months

  • Fundamental changes in the quality of life according to questionnaires

    6 months

Study Arms (2)

100 patients with stabile chronic heart failure with remote control

Group 1 is the intervention group, their health status will be monitored telemetrically for a half year by several electronic devices (for measurement of hearth frequency, blood pressure, blood saturation and periodically ECG recordings). Data will be periodically transmitted to the doctor in the ambulance. If measured data will indicated any worsening of heath (decompensation of circulation), physician will adjust the treatment remotely.

Behavioral: Telemedicine correction of medical treatmentBehavioral: Education for proper lifestyle

Non-intervention group: 100 patients with stabile chronic heart failure without remote control

Group 2 with patients with chronic heart failure in the non-intervention group, they will not be contacted by own physician for half a year - the planned periodic control will be scheduled after half a year.

Interventions

On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine

100 patients with stabile chronic heart failure with remote control

Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle

100 patients with stabile chronic heart failure with remote control

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with congestive heart failure with ejection fraction less than 45%

You may qualify if:

  • Congestive heart failure (CHF), NYHA II - VI (any genesis)
  • EF less then 45%, any rhythm (sinus or atrial fibrillation)
  • More as two months stable condition
  • Complete treatment according to recommendations (guidelines): ACEI (alternatively ARNI / sartan) + diuretics + betablockers (as alternative digitalis)
  • Without hospitalization with CHF decompensation more as two months before enrolment

You may not qualify if:

  • malignant diseases
  • planned cardiac surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Heart Failure

Interventions

Educational Status

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Socioeconomic FactorsPopulation Characteristics

Study Officials

  • Eva Goncalvesova

    National Institute of Vascular and Heart Diseases Bratislava

    PRINCIPAL INVESTIGATOR
  • Fedor Lehocki

    Slovak University of Technology in Bratislava

    STUDY CHAIR
  • Jozef Benacka

    Trnava University in Trnava

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2023

First Posted

June 2, 2023

Study Start

September 1, 2023

Primary Completion

May 1, 2024

Study Completion

September 1, 2024

Last Updated

June 2, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

No.